Drug intelligence / Profile preview

Hylo-Touch

Development stage: Preclinical
Lead developer: Sparsha Pharma International
Modality: Hydrogel Systems → Drug Delivery Systems
Administration: Transdermal

Overview

Hylo-Touch is a transdermal patch developed by Sparsha Pharma International, utilizing their proprietary "softtip" hydrogel technology. This "smart" transdermal delivery system is designed to allow active ingredients to penetrate the skin deeply, providing moisture and anti-aging benefits. While listed in Sparsha Pharma's R&D pipeline alongside pharmaceutical products, Hylo-Touch is primarily positioned for cosmetic and dermatological applications focusing on skin hydration. Specific details regarding the active ingredients, biological targets, and formal clinical development phases are not publicly available.

Brand names: Hylo-Touch

Beyond the preview

Go deeper on Hylo-Touch.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hylo-Touch.

Explore the full profile